| | PPS patients without maculopathy (n = 93 patients) | PPS patients with maculopathy (n = 4 patients) |
| Age, mean, years (median, range) | 63 (67, 22–94) | 73 (72, 67–81) |
| Race, no. (%) | | | White | 69 (74) | 3 (75) | Black | 1 (1) | 0 (0) | Asian/Indian | 10 (11) | 0 (0) | Middle Eastern | 0 (0) | 0 (0) | Hispanic | 3 (3) | 0 (0) | Native American | 1 (1) | 0 (0) | Unknown | 8 (9) | 1 (25) | Mixed | 1 (1) | 0 (0) |
| Sex, no. (%) | | | Male | 12 (13) | 0 (0) | Female | 81 (87) | 4 (100) |
| BMI, mean, kg/m ^ 2 (median, range) | 28 (27, 18–51) | 23 (23, 21–25) |
| Interval from date of IC diagnosis until now, mean, years (median, range) | 9 (8, 1–43) | 14 (14, 6–20) |
| Duration of PPS use, mean, years (median, range) | 3 (1, 0–13) | 12 (11, 6–19) |
| PPS daily dose, mean, mg (median, range) | 295 (30, 100–400) | 394 (400, 378–400) |
| PPS daily dose by body weight, mean, mg/kg (median, range) | 4 (4, 2–8) | 7 (6, 5–8) |
| Cumulative PPS exposure to date, mean, g (median, range) | 295 (113, 2–1371) | 1701 (1607, 812–2776) |
| BCVA OD logarithmic mean (median, range) | 0.19 (0.10, 0.00–0.88) | 0.6 (0.30, 0.00–1.90) |
| Snellen equivalent mean (median, range) | 20/30 (20/25, 20/20–20/150) | 20/80 (20/40–20/1600) |
| BCVA OS logarithmic mean (median, range) | 0.16 (0.10, 0.00–0.54) | 0.7 (0.40, 0.10–1.90) |
| Snellen equivalent mean (median, range) | 20/30 (20/25, 20/20–20/70) | 20/100 (20/50, 20/25–20/1600) |
|
|